Fabricating polydopamine-coated MoSe 2 -wrapped hollow mesoporous silica nanoplatform for controlled drug release and chemo-photothermal therapy

• Published in: International journal of nanomedicine Vol. 13; pp. 7607 - 7621
• Main Authors: Chai, Song, Kan, Shifeng, Sun, Ran, Zhou, Ruijuan, Sun, Yi, Chen, Wenhua, Yu, Bo
• Format: Journal Article
• Language: English
• Published: New Zealand 01.11.2018
• Subjects: Animals; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Antineoplastic Agents - therapeutic use; Breast Neoplasms - drug therapy; Breast Neoplasms - pathology; Cell Death; Cell Line, Tumor; Delayed-Action Preparations - therapeutic use; Doxorubicin - chemistry; Doxorubicin - pharmacokinetics; Doxorubicin - pharmacology; Doxorubicin - therapeutic use; Drug Liberation; Female; Humans; Hydrodynamics; Hydrogen-Ion Concentration; Hyperthermia, Induced; Indoles - chemistry; Mice, Inbred BALB C; Mice, Nude; Molybdenum - chemistry; Nanoparticles - chemistry; Nanoparticles - ultrastructure; Phototherapy; Polymers - chemistry; Rats, Sprague-Dawley; Silicon Dioxide - chemistry; Tissue Distribution; polydopamine; chemo- photothermal therapy; MoSe2; hollow mesoporous silica nanoparticles
• ISSN: 1178-2013; 1178-2013
• DOI: 10.2147/IJN.S181681

Integration of several types of therapeutic agents into one nanoplatform to enhance treatment efficacy is being more widely used for cancer therapy. Herein, a biocompatible polydopamine (PDA)-coated MoSe -wrapped doxorubicin (DOX)-loaded hollow mesoporous silica nanoparticles (HMSNs) nanoplatform (PM@HMSNs-DOX) was fabricated for dual-sensitive drug release and chemo-photothermal therapy for enhancing the therapeutic effects on breast cancer. The HMSNs were obtained by a "structural difference-based selective etching" strategy and served as the drug carrier, exhibiting a high DOX loading capacity of 427 mg/g HMSNs-NH , and then wrapped with PDA-coated MoSe layer to form PM@HMSNs-DOX. Various techniques proved the successful fabrication of the nanocomposites. The formed PM@HMSNs-DOX nanocomposites exhibited good biocompatibility, good stability, and super-additive photothermal conversion efficiency due to the cooperation of MoSe and PDA. Simultaneously, the pH/near-infrared-responsive drug release profile was observed, which could enhance the synergistic therapeutic anticancer effect. The antitumor effects of PM@HMSNs-DOX were evaluated both in vitro and in vivo, demonstrating that the synergistic therapeutic efficacy was significantly superior to any monotherapy. Also, in vivo pharmacokinetics studies showed that PM@HMSNs-DOX had a much longer circulation time than free DOX. In addition, in vitro and in vivo toxicity studies certified that PM@HMSNs are suitable as biocompatible agents. Our nanoplatform loaded with DOX displays pH/near-infrared-induced chemotherapy and excellent photothermal therapy, which hold great potential for cancer treatment.